cannabis patient care
|
vol. 2 no. 4 cannapatientcare.com
8
data focus
PTSD by the Numbers
PRODUCT TYPE
3.2%
Wax
0.8%
Other
72.8%
*included
23.2%
Flower
*"Included" means the user did not provide a specific product type.
SPECIFIC CONSUMPTION METHOD
68.8%
*included
7.2%
Vape pen
6.4%
Bong
5.6%
Other
4.8%
Vaporizer
2.4%
Joint
1.6%
Tincture
0.8%
Chocolate Bar
*"Included" means the user did not provide a specific consumption method.
2.4%
Orally
CONSUMPTION METHOD
97.6%
Inhaled
OVERALL RATING
27.2%
Score of 4
52%
Score of 5
16%
Score of 3
3.2%
Score of 2
1.6%
Score of 0
Data supplied by Tetragram as of November 21, 2021
G
ATHERING REAL WORLD data for medical cannabis pa-
tients is challenging, but the potential benefits to fel-
low patients could be outstanding. Tetragram, found-
ed by Otha Smith, is a mobile app that allows users
to anonymously track cannabis products enabling them to find
the best products that suit their needs. Here, Tetragam shares
some of the most recent data tied to patients reporting symp-
tom management for post-traumatic stress disorder (PTSD) to
see what type of products patients are finding useful, how they
are consuming it, and more.
Patients that selected PTSD for as their primary symptom
equaled 125 sessions. Of those sessions, 21.35 reported tetrahy-
drocannabinol (THC), 7.5 reported tetrahydrocannabinolic acid
(THCA), 1.7 reported cannabidiol (CBD), 0.81 reported cannabid-
iolic acid (CBDA), 0.04 reported tetrahydrocannabivarin (THCV),
and 0.03 reported cannabidivarin (CBDV) in their product.
